AOD-9604 Results Timeline: What Studies Measured, and When

Questions about how quickly a compound "works" are really questions about study design: what endpoint was measured, in which species or population, and at which timepoint the measurement was taken. For AOD-9604, the verified literature summarised on this page does not contain a human trial timeline with week-by-week outcome measurements, and this page does not construct one. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision.

What a "results timeline" means in research terms

In clinical and preclinical research generally, a timeline has three separate components that are often blurred together in popular writing:

• Pharmacokinetic timing — how long a substance remains measurable in blood, plasma or tissue after administration. This is measured in minutes and hours, not weeks.
• Biomarker timing — how long before a laboratory value (for example, a hormone or metabolic marker) changes relative to baseline.
• Clinical endpoint timing — how long before a structural, functional or symptomatic outcome changes, typically assessed at pre-specified visits over weeks or months.

A compound can be detectable within hours and still have no measured endpoint change at any timepoint, or have a measured biomarker shift with no corresponding clinical endpoint. Separating these three layers is what makes a timeline meaningful rather than anecdotal.

The shape of the verified AOD-9604 record

Across the verified papers summarised here, the record is weighted toward animal modelling, review-level synthesis and analytical chemistry rather than controlled human outcome trials: researchers examined intra-articular AOD9604 with or without hyaluronic acid in a rabbit osteoarthritis model (PMID 26275694), reviewed approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance (PMID 41966639), described the emerging landscape of performance-enhancing peptides modulating the GH–IGF1 axis and the gap between clinical evidence and patient self-administration (PMID 42395176), and reported an analytical workflow for determining peptidic and non-peptidic doping agents in dried and liquid blood matrices (PMID 42328738).

Animal work: an intra-articular joint model

The study that examined AOD9604 most directly in the verified set was an animal experiment: researchers evaluated the effect of intra-articular injection of AOD9604, given with or without hyaluronic acid, in a rabbit osteoarthritis model (PMID 26275694). Two features of that design matter for timeline questions. First, the route was intra-articular — delivery directly into a joint space — which is not interchangeable with systemic administration when reasoning about onset or duration. Second, the subjects were rabbits with experimentally induced osteoarthritis, so any timepoint in that study describes a rabbit joint model and cannot be read across to a human timeline for body composition, recovery or performance.

Animal joint studies of this type conventionally assess outcomes at terminal or interim timepoints defined by the protocol rather than by how a subject feels, which is another reason preclinical designs rarely translate into the "by week X" framing used in consumer discussion. The study design described in the published report was comparative — AOD9604 alone versus AOD9604 combined with hyaluronic acid — rather than a dose-ranging timeline study (PMID 26275694).

Review coverage: approval status as a dividing line

Review articles in the verified set approached peptides by regulatory category rather than by promised result windows. One 2026 review in Sports Medicine addressed the safety and efficacy of approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance (PMID 41966639). Reviews structured this way are useful for timeline questions in an indirect sense: they indicate whether a given compound sits in a literature with completed controlled trials, or in a literature dominated by preclinical work, case reports and marketing claims. A compound in the latter category does not have an evidence-based onset window to report.

GH–IGF-1 axis peptides and the self-administration gap

A 2026 review in Frontiers in Endocrinology described the emerging landscape of performance-enhancing peptides that modulate the GH–IGF1 axis and explicitly framed the distance between clinical evidence and patient self-administration (PMID 42395176). That framing is relevant to results-timeline questions because much of what circulates as a "timeline" for growth-hormone-related peptides originates in self-reported use rather than in protocol-defined measurement. Self-report has no fixed baseline, no blinding and no standardised assessment schedule, so apparent onset windows drawn from it describe reporting behaviour as much as biology.

Analytical work: a different kind of clock

Anti-doping analytical research measures a timeline of a different kind — detectability. A 2026 paper in The Analyst reported a rapid and harmonised analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices (PMID 42328738). Detection-window research answers the question "for how long after administration can this be measured in a sample?" It does not answer "when does an effect appear?", and the two are frequently conflated when people search for timelines.

Timepoints by evidence type

Why numeric week-by-week claims are not supported here

Specific statements such as "measurable change at four weeks" or "peak effect by twelve weeks" require a study that measured that endpoint at that timepoint in that population. The verified papers summarised on this page include an animal joint experiment, two reviews and an analytical method paper (PMID 26275694, PMID 41966639, PMID 42395176, PMID 42328738). Where a timepoint, dose or magnitude of change is not available within that verified scope, this page omits it rather than estimating it. Readers encountering confident numeric timelines elsewhere can usefully ask three questions: which study, which species, and which endpoint.

Route of administration changes the question

Timeline discussion often assumes a single route, but the verified AOD-9604 animal study used intra-articular delivery into the joint of a rabbit osteoarthritis model (PMID 26275694). Local delivery into a joint, systemic injection and oral delivery produce different exposure profiles, different tissue concentrations and therefore different plausible onset patterns. A timeline derived from one route is not transferable to another, and a timeline derived from an animal model is not transferable to people.

Adverse Events in the AOD-9604 Literature: What Studies Report

Safety reporting in the verified set is review-level rather than trial-level. The 2026 Sports Medicine review assessed safety alongside efficacy for approved and unapproved peptide therapies used in musculoskeletal injury and athletic performance contexts (PMID 41966639), and the 2026 Frontiers in Endocrinology review addressed performance-enhancing peptides acting on the GH–IGF1 axis in the context of patient self-administration (PMID 42395176). Reviews that foreground unapproved use and self-administration implicitly flag a reporting problem: adverse events occurring outside clinical supervision are not systematically captured, so absence of reported events in a non-trial literature is not evidence of absence. The animal joint study described a rabbit osteoarthritis model rather than human tolerability (PMID 26275694). No specific adverse-event rates are stated on this page because none are available within the verified scope.

How detection timing is studied

For readers interested in the analytical side, the 2026 Analyst paper reported a workflow intended to be rapid and harmonised across dried and liquid blood matrices for peptidic and non-peptidic doping agents (PMID 42328738). Dried blood sampling has drawn interest in anti-doping contexts because of logistics and stability, and methodological papers of this kind define what can be measured and in which matrix — a prerequisite for any later work describing how long an agent remains detectable.

What would be needed to answer the timing question

1. A controlled human trial with a defined population and a pre-specified primary endpoint.
2. Measurement at multiple scheduled timepoints, with a baseline and a comparator arm.
3. Blinded assessment, so that expectation does not shape reported change.
4. Reporting of both the magnitude and the variability of change at each timepoint, not just an average.
5. Replication, so that one trial's timeline is not treated as a general rule.

Until such data exist and are published, the honest answer to a timing question is a description of the evidence that does exist — animal, review and analytical work (PMID 26275694, PMID 41966639) — together with an explicit statement of the gap.

Related reading

For a broader overview of what the literature describes about this peptide, see the hub page: AOD-9604 overview.

References

• Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model (Annals of Clinical and Laboratory Science, 2015)
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)
• The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration (Frontiers in Endocrinology, 2026)
• Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices (The Analyst, 2026)